SGLT-2 inhibitors in diabetes: a focus on renoprotection

SUMMARY Type 2 diabetes mellitus is an important public health problem, with a significant impact on cardiovascular morbidity and mortality and an important risk factor for chronic kidney disease. Various hypoglycemic therapies have proved to be beneficial to clinical outcomes, while others have failed to provide an improvement in cardiovascular and renal failure, only reducing blood glucose levels. Recently, sodium-glucose cotransporter-2 (SGLT2) inhibitors, represented by the empagliflozin, dapagliflozin, and canagliflozin, have been showing satisfactory and strong results in several clinical trials, especially regarding the reduction of cardiovascular mortality, reduction of hospitalization due to heart failure, reduction of albuminuria, and long-term maintenance of the glomerular filtration rate. The benefit from SGLT2 inhibitors stems from its main mechanism of action, which occurs in the proximal tubule of the nephron, causing glycosuria, and a consequent increase in natriuresis. This leads to increased sodium intake by the juxtaglomerular apparatus, activating the tubule glomerular-feedback and, finally, reducing intraglomerular hypertension, a frequent physiopathological condition in kidney disease caused by diabetes. In addition, this class of medication presents an appropriate safety profile, and its most frequently reported complication is an increase in the incidence of genital infections. Thus, these hypoglycemic agents gained space in practical recommendations f...
Source: Revista da Associacao Medica Brasileira - Category: General Medicine Source Type: research

Related Links:

ConclusionOur analysis provided strong evidence to indicate a causal relationship between WC and increased risk of CHD.
Source: Molecular Genetics & Genomic Medicine - Category: Genetics & Stem Cells Authors: Tags: ORIGINAL ARTICLE Source Type: research
Publication date: Available online 27 February 2020Source: The American Journal of SurgeryAuthor(s): Lawrence A. Lavery, Kathryn E. Davis, Javier La Fontaine, J. David Farrar, Kavita Bhavan, Orhan K. Oz, Peter A. Crisologo
Source: The American Journal of Surgery - Category: Surgery Source Type: research
The objective of this study was to examine the effect of metabolic syndrome on 30-day postoperative complications following corrective surgery for the adult spinal deformity (ASD). Summary of Background Data: Metabolic syndrome has been shown to increase the risk of cardiovascular morbidity and mortality. Few studies have examined the effect of metabolic syndrome on patients with ASD undergoing surgery. Materials and Methods: We performed a retrospective cohort study of patients who underwent spinal fusion for ASD. Patients were divided into 2 groups based on the presence or absence of metabolic syndrome, which was d...
Source: Journal of Spinal Disorders and Techniques - Category: Surgery Tags: Primary Research Source Type: research
AbstractBackgroundAcute vasoreactivity testing (AVT) which reflects the compliance of the pulmonary vascular bed has been proven to be of prognostic value. The purpose of the present study is to explore the sex differences of hemodynamics during the AVT and their impact on event ‐free survival in patients with chronic thromboembolic pulmonary hypertension (CTEPH).MethodsEighty ‐six patients underwent a right heart catheterization and AVT at Shanghai Pulmonary Hospital from February 2009 to February 2018. Univariate and multiple stepwise regression analysis were performed to determine the predictors of independent event...
Source: The Clinical Respiratory Journal - Category: Respiratory Medicine Authors: Tags: ORIGINAL ARTICLE Source Type: research
Publication date: Available online 26 February 2020Source: Journal of Advanced ResearchAuthor(s): Heng Zhang, Yaqian Huang, Selena Chen, Chaoshu Tang, Guang Wang, Junbao Du, Hongfang Jin
Source: Journal of Advanced Research - Category: Research Source Type: research
Conditions:   Diabetes Mellitus;   Cardiovascular Diseases Interventions:   Drug: Renin-angiotensin-aldosterone system inhibitors;   Drug: Beta blocker;   Drug: SGLT2 Inhibitor - Sodium Glucose Cotransporter Subtype 2 Inhibitor Product Sponsors:   National Heart Centre Singapore;   Singapore General Hospital;   Mackay Memorial Hospital;   National Taiwan University Hospital;   Peking University People's Hospital;   Medanta, The Medicity, India;   Public Health&...
Source: - Category: Research Source Type: clinical trials
Conditions:   Hypertension;   Salt; Excess Interventions:   Device: Salt-meter;   Behavioral: Education Sponsor:   Mahidol University Active, not recruiting
Source: - Category: Research Source Type: clinical trials
Conditions:   Pre-hypertension;   Hypertension Intervention:   Behavioral: WOW Intervention Sponsor:   Johns Hopkins University Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Conditions:   Diabetes Mellitus, Type 2;   Diabetes;   Diabetes type2;   Type2 Diabetes;   Type 2 Diabetes;   Type II Diabetes;   Hypertension;   High Blood Pressure Interventions:   Other: DASH4D diet;   Other: comparison diet;   Other: higher sodium;   Other: lower sodium Sponsors:   Johns Hopkins University;   Beth Israel Deaconess Medical Center Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Please wait while the activity loads. If this activity does not load, try refreshing your browser. Also, this page requires javascript. Please visit using a browser with javascript enabled. If loading fails, click here to try again Click on the 'Start' button to begin the mock test. After answering all questions, click on the 'Get Results' button to display your score and the explanations. There is no time limit for this mock test. Start Congratulations - you have completed DM / DNB Cardiology Entrance Mock Test 10. You scored %%SCORE%% out of %%TOTAL%%. Your performance has been rat...
Source: Cardiophile MD - Category: Cardiology Authors: Tags: Cardiology MCQ DM / DNB Cardiology Entrance Featured Source Type: blogs
More News: Canagliflozin | Cardiology | Cardiovascular | Chronic Kidney Disease | Clinical Trials | Dapagliflozin | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Empagliflozin | Endocrinology | Forxiga | General Medicine | Heart | Heart Failure | Hypertension | International Medicine & Public Health | Invokana | Jardiance | Renal Failure | SGLT2 Inhibitors | Sodium | Urology & Nephrology